Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Biogen | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Biogen

Revenues up 7% in the quarter driven by TECFIDERA

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Biogen

1Q Revenues: $2.7 billion (+7%)

1Q Earnings: $971 million (+18%)

Comments: Growth was driven by TECFIDERA sales, up 15% to $946 million. ELOCTATE sales were $108 million, up 101%, and ALPROLIX sales were $75 million, up 74%. Revenues were partially offset by a decrease in worldwide interferon sales, with AVONEX down 19%. TYSABRI sales were $477 million, up 3%.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters